233 related articles for article (PubMed ID: 37509075)
1. Altered TRPM7-Dependent Calcium Influx in Natural Killer Cells of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
Du Preez S; Eaton-Fitch N; Smith PK; Marshall-Gradisnik S
Biomolecules; 2023 Jun; 13(7):. PubMed ID: 37509075
[TBL] [Abstract][Full Text] [Related]
2. Impaired TRPM3-dependent calcium influx and restoration using Naltrexone in natural killer cells of myalgic encephalomyelitis/chronic fatigue syndrome patients.
Eaton-Fitch N; Du Preez S; Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
J Transl Med; 2022 Feb; 20(1):94. PubMed ID: 35172836
[TBL] [Abstract][Full Text] [Related]
3. Validation of impaired Transient Receptor Potential Melastatin 3 ion channel activity in natural killer cells from Chronic Fatigue Syndrome/ Myalgic Encephalomyelitis patients.
Cabanas H; Muraki K; Balinas C; Eaton-Fitch N; Staines D; Marshall-Gradisnik S
Mol Med; 2019 Apr; 25(1):14. PubMed ID: 31014226
[TBL] [Abstract][Full Text] [Related]
4. Characterization of IL-2 Stimulation and TRPM7 Pharmacomodulation in NK Cell Cytotoxicity and Channel Co-Localization with PIP
Du Preez S; Eaton-Fitch N; Cabanas H; Staines D; Marshall-Gradisnik S
Int J Environ Res Public Health; 2021 Nov; 18(22):. PubMed ID: 34831634
[TBL] [Abstract][Full Text] [Related]
5. Loss of Transient Receptor Potential Melastatin 3 ion channel function in natural killer cells from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Cabanas H; Muraki K; Eaton N; Balinas C; Staines D; Marshall-Gradisnik S
Mol Med; 2018 Aug; 24(1):44. PubMed ID: 30134818
[TBL] [Abstract][Full Text] [Related]
6. Transient receptor potential melastatin 2 channels are overexpressed in myalgic encephalomyelitis/chronic fatigue syndrome patients.
Balinas C; Cabanas H; Staines D; Marshall-Gradisnik S
J Transl Med; 2019 Dec; 17(1):401. PubMed ID: 31796045
[TBL] [Abstract][Full Text] [Related]
7. The effect of IL-2 stimulation and treatment of TRPM3 on channel co-localisation with PIP
Eaton-Fitch N; Cabanas H; du Preez S; Staines D; Marshall-Gradisnik S
J Transl Med; 2021 Jul; 19(1):306. PubMed ID: 34266470
[TBL] [Abstract][Full Text] [Related]
8. Potential Therapeutic Benefit of Low Dose Naltrexone in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Role of Transient Receptor Potential Melastatin 3 Ion Channels in Pathophysiology and Treatment.
Cabanas H; Muraki K; Eaton-Fitch N; Staines DR; Marshall-Gradisnik S
Front Immunol; 2021; 12():687806. PubMed ID: 34326841
[TBL] [Abstract][Full Text] [Related]
9. Novel identification and characterisation of Transient receptor potential melastatin 3 ion channels on Natural Killer cells and B lymphocytes: effects on cell signalling in Chronic fatigue syndrome/Myalgic encephalomyelitis patients.
Nguyen T; Staines D; Nilius B; Smith P; Marshall-Gradisnik S
Biol Res; 2016 May; 49(1):27. PubMed ID: 27245705
[TBL] [Abstract][Full Text] [Related]
10. Impaired calcium mobilization in natural killer cells from chronic fatigue syndrome/myalgic encephalomyelitis patients is associated with transient receptor potential melastatin 3 ion channels.
Nguyen T; Johnston S; Clarke L; Smith P; Staines D; Marshall-Gradisnik S
Clin Exp Immunol; 2017 Feb; 187(2):284-293. PubMed ID: 27727448
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone Restores Impaired Transient Receptor Potential Melastatin 3 Ion Channel Function in Natural Killer Cells From Myalgic Encephalomyelitis/Chronic Fatigue Syndrome Patients.
Cabanas H; Muraki K; Staines D; Marshall-Gradisnik S
Front Immunol; 2019; 10():2545. PubMed ID: 31736966
[TBL] [Abstract][Full Text] [Related]
12. Potential Implications of Mammalian Transient Receptor Potential Melastatin 7 in the Pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: A Review.
Du Preez S; Cabanas H; Staines D; Marshall-Gradisnik S
Int J Environ Res Public Health; 2021 Oct; 18(20):. PubMed ID: 34682454
[TBL] [Abstract][Full Text] [Related]
13. Transient receptor potential melastatin 3 dysfunction in post COVID-19 condition and myalgic encephalomyelitis/chronic fatigue syndrome patients.
Sasso EM; Muraki K; Eaton-Fitch N; Smith P; Lesslar OL; Deed G; Marshall-Gradisnik S
Mol Med; 2022 Aug; 28(1):98. PubMed ID: 35986236
[TBL] [Abstract][Full Text] [Related]
14. Investigation into the restoration of TRPM3 ion channel activity in post-COVID-19 condition: a potential pharmacotherapeutic target.
Sasso EM; Muraki K; Eaton-Fitch N; Smith P; Jeremijenko A; Griffin P; Marshall-Gradisnik S
Front Immunol; 2024; 15():1264702. PubMed ID: 38765011
[TBL] [Abstract][Full Text] [Related]
15. Single nucleotide polymorphisms and genotypes of transient receptor potential ion channel and acetylcholine receptor genes from isolated B lymphocytes in myalgic encephalomyelitis/chronic fatigue syndrome patients.
Marshall-Gradisnik S; Johnston S; Chacko A; Nguyen T; Smith P; Staines D
J Int Med Res; 2016 Dec; 44(6):1381-1394. PubMed ID: 27834303
[TBL] [Abstract][Full Text] [Related]
16. Natural killer cells and single nucleotide polymorphisms of specific ion channels and receptor genes in myalgic encephalomyelitis/chronic fatigue syndrome.
Marshall-Gradisnik S; Huth T; Chacko A; Johnston S; Smith P; Staines D
Appl Clin Genet; 2016; 9():39-47. PubMed ID: 27099524
[TBL] [Abstract][Full Text] [Related]
17. Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation.
Eaton N; Cabanas H; Balinas C; Klein A; Staines D; Marshall-Gradisnik S
BMC Pharmacol Toxicol; 2018 Mar; 19(1):12. PubMed ID: 29587879
[TBL] [Abstract][Full Text] [Related]
18. Natural killer cytotoxicity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS): a multi-site clinical assessment of ME/CFS (MCAM) sub-study.
Querec TD; Lin JS; Chen Y; Helton B; Kogelnik AM; Klimas NG; Peterson DL; Bateman L; Lapp C; Podell RN; Natelson BH; Unger ER;
J Transl Med; 2023 Apr; 21(1):242. PubMed ID: 37013608
[TBL] [Abstract][Full Text] [Related]
19. ERK1/2, MEK1/2 and p38 downstream signalling molecules impaired in CD56 dim CD16+ and CD56 bright CD16 dim/- natural killer cells in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
Huth TK; Staines D; Marshall-Gradisnik S
J Transl Med; 2016 Apr; 14():97. PubMed ID: 27098723
[TBL] [Abstract][Full Text] [Related]
20. A systematic review of natural killer cells profile and cytotoxic function in myalgic encephalomyelitis/chronic fatigue syndrome.
Eaton-Fitch N; du Preez S; Cabanas H; Staines D; Marshall-Gradisnik S
Syst Rev; 2019 Nov; 8(1):279. PubMed ID: 31727160
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
